18 completed, 4 unknown, 1 not yet recruiting, 1 withdrawn. 16 Phase 1, 6 Phase 3, 2 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 16 | Completed 12, Unknown 4 |
| Phase 3 | 6 | Completed 4, Not yet recruiting 1, Withdrawn 1 |
| Phase 4 | 2 | Completed 2 |
Follow Alvogen Korea: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 3 Study of Viloxazine ER Capsules in Korean Children and Adolescents With ADHD AK-D101, Placebo - Attention Deficit Hyperactivity Disorder, Attention-Deficit / Hyperactivity Disorder | Phase 3 | Not yet recruiting | Alvogen Korea | 156 | 2026-07-01 | 2026-07-02 |
| Phase IV Study of Qsymia in Obese Patients Qsymia 3.75Mg-23Mg Extended Release Capsule, Qsymia 7.5Mg-46Mg Extended Release Capsule, Qsymia 11.25Mg-69Mg Extended Release Capsule - Obesity | Phase 4 | Completed | Alvogen Korea | 232 | 2021-09-17 | 2024-01-31 |
| AK-R215 Pharmacokinetic Study Phase I AK-R215, Bazedoxifene 20 mg, Cholecalciferol 800IU - Healthy | Phase 1 | Unknown | Alvogen Korea | 52 | 2017-07-13 | 2017-10-25 |
| Clinical Trial to Evaluate the Efficacy and Safety of DP-R212 DP-R212, C1-R212, C2-R212 - Hypertension, Hypercholesterolemia | Phase 3 | Withdrawn | Alvogen Korea | 2017-02-01 | 2017-06-05 | |
| DP-R213 Phase 1 Pharmacokinetics Study DP-R213, Raloxifene, Cholecaliferol - Healthy | Phase 1 | Completed | Alvogen Korea | 46 | 2017-01-03 | 2017-06-05 |
| A Phase 1 Drug Drug Interaction Clinical Trial of C1-R215 and C2-R215 in Healthy Male Volunteers Treatment B, Treatment C, Treatment BC - Healthy | Phase 1 | Unknown | Alvogen Korea | 24 | 2016-12-01 | 2016-12-29 |
| DP-R212 Pharmacokinetic Study Phase I DP-R212, Amlodipine, Rosuvastatin - Healthy | Phase 1 | Unknown | Alvogen Korea | 36 | 2016-07-01 | 2016-06-27 |
| DP-R213 Pharmacokinetics Study DP-R213, Raloxifene, Cholecaliferol - Healthy | Phase 1 | Completed | Alvogen Korea | 61 | 2016-05-01 | 2016-11-01 |
| DP-R212 Pharmacokinetic Study Amlodipine, Rosuvastatin - Hypertension, Hyperlipidemias | Phase 1 | Unknown | Alvogen Korea | 38 | 2016-05-01 | 2016-06-03 |
| DP-R208 Pharmacokinetic Study DP-R208, Candesartan cilexetil, Rosuvastatin - Healthy | Phase 1 | Completed | Alvogen Korea | 37 | 2016-03-01 | 2016-06-08 |
| A Drug-drug Interaction Study of DP-R213 Cholecalciferol, Raloxifene, Cholecalciferol and Raloxifene co-administration - Healthy | Phase 1 | Completed | Alvogen Korea | 24 | 2016-01-01 | 2016-03-11 |
| Phase III Clinical Trial to Evaluate the Efficacy and Safety of DP-R208 and Each Monotherapy DP-R208, Candesartan32mg, Rosuvastatin 20mg - Hypertension, Cholesterolemia | Phase 3 | Completed | Alvogen Korea | 219 | 2015-12-01 | 2016-12-26 |
| Clinical Trial to Compare the Pharmacokinetics of DP-R208 DP-R208, Candesartan cilexetil, Rosuvastatin - Healthy | Phase 1 | Completed | Alvogen Korea | 40 | 2015-01-01 | 2016-03-23 |
| A Study to Compare the Pharmacokinetics of DP-R207 in Comparison to Each Component Administered Alone DP-R207, Rosuvastatin, Ezetimibe - Healthy Volunteers | Phase 1 | Completed | Alvogen Korea | 66 | 2014-12-01 | 2016-04-06 |
| Efficacy/Safety of DP-R207 Tablet Versus CRESTOR Tablet in Patients With Primary Hypercholesterolemia Rosuvastatin 5mg, DP-R207 5/10mg, Rosuvastatin 10mg - Primary Hypercholesterolemia | Phase 3 | Completed | Alvogen Korea | 379 | 2014-07-01 | 2015-05-15 |
| Pharmacokinetic Drug Interaction Between Candesartan and Rosuvastatin Candesartan, Rosuvastatin - Healthy | Phase 1 | Completed | Alvogen Korea | 40 | 2014-02-01 | 2014-03-05 |
| Isobide Solution and Meniace Tablets Compared to Monotherapy With Meniace Tablets Meniace, Isobide - Meniere's Disease | Phase 4 | Completed | Alvogen Korea | 220 | 2013-02-01 | 2016-03-24 |
| Clinical Trial to Evaluate Efficacy and Safety of DP-R202 and Anplag in Patients With Artery Occlusive Disease DP-R202, Anplag tab - Peripheral Arterial Disease | Phase 3 | Completed | Alvogen Korea | 151 | 2012-10-01 | 2016-11-01 |
| Safety and Pharmacokinetic Characteristics of DP-R206(Vitamin D3) in Healthy Adult Volunteers Vitamin D3, DP-R206 - Healthy | Phase 1 | Completed | Alvogen Korea | 36 | 2012-03-01 | 2016-11-01 |
| Phase III Clinical Trial of DP-R206 and Bonvia In Postmenopausal Women With Osteoporosis Test group, Reference group - Postmenopausal Women With Osteoporosis | Phase 3 | Completed | Alvogen Korea | 201 | 2011-12-01 | 2016-11-01 |
Showing 20 of 24. Sign in to see all of them.
Hypertension (3) · Attention Deficit Disorder with Hyperactivity (1) · Hypercholesterolemia (1) · Hyperlipidemias (1) · Meniere Disease (1) · Obesity (1) · Peripheral Arterial Disease (1)
Rosuvastatin Calcium (8) · Cholecalciferol (4) · Raloxifene Hydrochloride (3) · Amlodipine (2) · DP-R206 (2) · Ezetimibe (2) · Ibandronic Acid (2) · bazedoxifene (2) · candesartan (2) · candesartan cilexetil (2) · Drug Evaluation (1) · Maintenance (1) · Qsymia (1)
South Korea (14)
ChangBeom Lee, M.D., Ph.D. (1) · Changkyu Park (1) · Jae Wook Ko, M.D., Ph.D (1) · Jae Wook Ko, MD, PhD (1) · JaeWook Ko, M.D., Ph.D. (1) · JangHee Hong, PhD. (1) · Min-Gul Kim, Ph.D (1) · Moo-il Kang, MD, PhD (1) · Won-ho Jeong, Ph.D. (1) · Yangsoo Jang, Ph.D. (1)